MRP-S17 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can reduce the activity of proteins involved in mTOR signaling. Given that mTOR can regulate protein synthesis and cell growth, inhibiting this pathway can lead to a reduction in the functional activity of MRP-S17 if it is implicated in these cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that suppresses the PI3K/Akt/mTOR pathway. By inhibiting this upstream signaling, LY294002 can indirectly decrease the activity of MRP-S17 if it is downstream of this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
WZB117 inhibits glucose transporter 1 (GLUT1), which could reduce the energy supply necessary for the proper function of MRP-S17 if it relies on high levels of glycolysis for its activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts protein trafficking by inhibiting ADP-ribosylation factor, which could affect the localization and function of MRP-S17 if it is dependent on vesicular transport. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which blocks the ERK/MAPK pathway. If MRP-S17 activity is modulated by MAPK signaling, U0126 could indirectly decrease its functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibition of p38 MAPK can suppress inflammatory responses and could indirectly affect MRP-S17 activity if it plays a role in inflammation or stress response pathways. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC 23766 inhibits Rac1, which is involved in actin cytoskeleton organization. Impairing actin polymerization might affect the cellular localization or function of MRP-S17 if it interacts with the cytoskeleton. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is involved in stress signaling pathways. If MRP-S17 is implicated in these pathways, JNK inhibition could lead to a decrease in its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor, leading to the inhibition of Akt phosphorylation. If MRP-S17 activity is regulated by the PI3K/Akt pathway, wortmannin could indirectly decrease its activity. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits protein synthesis by interfering with the translocation step in protein elongation. This can lead to a general decrease in protein levels, potentially affecting the expression and function of MRP-S17. | ||||||